BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 21084263)

  • 1. What's in a name? Neuronal intermediate filament inclusion disease (NIFID), frontotemporal lobar degeneration-intermediate filament (FTLD-IF) or frontotemporal lobar degeneration-fused in sarcoma (FTLD-FUS)?
    Menon R; Baborie A; Jaros E; Mann DM; Ray PS; Larner AJ
    J Neurol Neurosurg Psychiatry; 2011 Dec; 82(12):1412-4. PubMed ID: 21084263
    [No Abstract]   [Full Text] [Related]  

  • 2. FUS immunogold labeling TEM analysis of the neuronal cytoplasmic inclusions of neuronal intermediate filament inclusion disease: a frontotemporal lobar degeneration with FUS proteinopathy.
    Page T; Gitcho MA; Mosaheb S; Carter D; Chakraverty S; Perry RH; Bigio EH; Gearing M; Ferrer I; Goate AM; Cairns NJ; Thorpe JR
    J Mol Neurosci; 2011 Nov; 45(3):409-21. PubMed ID: 21603978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotypic variability within the inclusion body spectrum of basophilic inclusion body disease and neuronal intermediate filament inclusion disease in frontotemporal lobar degenerations with FUS-positive inclusions.
    Gelpi E; Lladó A; Clarimón J; Rey MJ; Rivera RM; Ezquerra M; Antonell A; Navarro-Otano J; Ribalta T; Piñol-Ripoll G; Pérez A; Valldeoriola F; Ferrer I
    J Neuropathol Exp Neurol; 2012 Sep; 71(9):795-805. PubMed ID: 22892522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies.
    Lashley T; Rohrer JD; Bandopadhyay R; Fry C; Ahmed Z; Isaacs AM; Brelstaff JH; Borroni B; Warren JD; Troakes C; King A; Al-Saraj S; Newcombe J; Quinn N; Ostergaard K; Schrøder HD; Bojsen-Møller M; Braendgaard H; Fox NC; Rossor MN; Lees AJ; Holton JL; Revesz T
    Brain; 2011 Sep; 134(Pt 9):2548-64. PubMed ID: 21752791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological features of FTLD-FUS in a Japanese population: analyses of nine cases.
    Kobayashi Z; Kawakami I; Arai T; Yokota O; Tsuchiya K; Kondo H; Shimomura Y; Haga C; Aoki N; Hasegawa M; Hosokawa M; Oshima K; Niizato K; Ishizu H; Terada S; Onaya M; Ikeda M; Oyanagi K; Nakano I; Murayama S; Akiyama H; Mizusawa H
    J Neurol Sci; 2013 Dec; 335(1-2):89-95. PubMed ID: 24050818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease.
    Neumann M; Roeber S; Kretzschmar HA; Rademakers R; Baker M; Mackenzie IR
    Acta Neuropathol; 2009 Nov; 118(5):605-16. PubMed ID: 19669651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spatial patterns of FUS-immunoreactive neuronal cytoplasmic inclusions (NCI) in neuronal intermediate filament inclusion disease (NIFID).
    Armstrong RA; Gearing M; Bigio EH; Cruz-Sanchez FF; Duyckaerts C; Mackenzie IR; Perry RH; Skullerud K; Yokoo H; Cairns NJ
    J Neural Transm (Vienna); 2011 Nov; 118(11):1651-7. PubMed ID: 21792670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear carrier and RNA-binding proteins in frontotemporal lobar degeneration associated with fused in sarcoma (FUS) pathological changes.
    Davidson YS; Robinson AC; Hu Q; Mishra M; Baborie A; Jaros E; Perry RH; Cairns NJ; Richardson A; Gerhard A; Neary D; Snowden JS; Bigio EH; Mann DM
    Neuropathol Appl Neurobiol; 2013 Feb; 39(2):157-65. PubMed ID: 22497712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct pathological subtypes of FTLD-FUS.
    Mackenzie IR; Munoz DG; Kusaka H; Yokota O; Ishihara K; Roeber S; Kretzschmar HA; Cairns NJ; Neumann M
    Acta Neuropathol; 2011 Feb; 121(2):207-18. PubMed ID: 21052700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transportin 1 colocalization with Fused in Sarcoma (FUS) inclusions is not characteristic for amyotrophic lateral sclerosis-FUS confirming disrupted nuclear import of mutant FUS and distinguishing it from frontotemporal lobar degeneration with FUS inclusions.
    Troakes C; Hortobágyi T; Vance C; Al-Sarraj S; Rogelj B; Shaw CE
    Neuropathol Appl Neurobiol; 2013 Aug; 39(5):553-61. PubMed ID: 22934812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel types of frontotemporal lobar degeneration: beyond tau and TDP-43.
    Mackenzie IR; Neumann M; Cairns NJ; Munoz DG; Isaacs AM
    J Mol Neurosci; 2011 Nov; 45(3):402-8. PubMed ID: 21603977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frontotemporal lobar degeneration: diversity of FTLD lesions.
    Seilhean D; Bielle F; Plu I; Duyckaerts C
    Rev Neurol (Paris); 2013 Oct; 169(10):786-92. PubMed ID: 24035575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basophilic inclusions and neuronal intermediate filament inclusions in amyotrophic lateral sclerosis and frontotemporal lobar degeneration.
    Ito H
    Neuropathology; 2014 Dec; 34(6):589-95. PubMed ID: 24673472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chorea as a clinical feature of the basophilic inclusion body disease subtype of fused-in-sarcoma-associated frontotemporal lobar degeneration.
    Kawakami I; Kobayashi Z; Arai T; Yokota O; Nonaka T; Aoki N; Niizato K; Oshima K; Higashi S; Katsuse O; Hosokawa M; Hasegawa M; Akiyama H
    Acta Neuropathol Commun; 2016 Apr; 4():36. PubMed ID: 27044537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene.
    Snowden JS; Hu Q; Rollinson S; Halliwell N; Robinson A; Davidson YS; Momeni P; Baborie A; Griffiths TD; Jaros E; Perry RH; Richardson A; Pickering-Brown SM; Neary D; Mann DM
    Acta Neuropathol; 2011 Jul; 122(1):99-110. PubMed ID: 21424531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FUS pathology in basophilic inclusion body disease.
    Munoz DG; Neumann M; Kusaka H; Yokota O; Ishihara K; Terada S; Kuroda S; Mackenzie IR
    Acta Neuropathol; 2009 Nov; 118(5):617-27. PubMed ID: 19830439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transportin1: a marker of FTLD-FUS.
    Brelstaff J; Lashley T; Holton JL; Lees AJ; Rossor MN; Bandopadhyay R; Revesz T
    Acta Neuropathol; 2011 Nov; 122(5):591-600. PubMed ID: 21847626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration.
    Seelaar H; Klijnsma KY; de Koning I; van der Lugt A; Chiu WZ; Azmani A; Rozemuller AJ; van Swieten JC
    J Neurol; 2010 May; 257(5):747-53. PubMed ID: 19946779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuronal cytoplasmic inclusions in tau, TDP-43, and FUS molecular subtypes of frontotemporal lobar degeneration share similar spatial patterns.
    A Armstrong R
    Folia Neuropathol; 2017; 55(3):185-192. PubMed ID: 28984110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topography of hemispheric white matter pathology in ten cases of neuronal intermediate filament inclusion disease.
    Armstrong RA
    Clin Neuropathol; 2018; 37(5):239-244. PubMed ID: 29956645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.